IDH2
Pathos AI Closes $62M Series C Funding Round
The financing will allow the firm to further develop its AI platform, develop drugs in best responders, and acquire new pipeline candidates.
FDA Approves Thermo Fisher Oncomine Dx Target Test as CDx for Servier's Voranigo Brain Cancer Drug
The approval expands the clinical indications for the test, which was previously approved as a CDx for non-small cell lung cancer, thyroid cancer, and bile duct cancer drugs.
FDA Approves Servier's Voranigo for Certain IDH-Mutated Gliomas
The approval marks the first targeted therapy commercially available for patients with grade 2 IDH-mutated glioma.
Royalty Pharma to Acquire Royalty Rights for Servier's Vorasidenib From Agios Pharmaceuticals
Agios plans to use proceeds from the deal to launch a treatment for thalassemia and sickle cell disease, and to expand its pipeline.
Servier Files for Vorasidenib Glioma Approvals in US, Europe
The firm is seeking approvals for vorasidenib in IDH1/2 mutated residual or recurrent grade 2 glioma based on the results of its Phase III INDIGO trial.
Apr 13, 2020
Mar 12, 2019